Climb Bio ITP data fuels near-term upside ahead of key catalyst events
Climb Bio reported favorable Phase 1b budoprutug data in ITP with strong B-cell depletion and meaningful platelet gains, including rituximab-exposed patients. Investors await late-summer PK/PD data for CLYM116 and Q4 readouts in membranous nephropathy and SLE, which could propel further upside if results meet expectations and support the broader BAFF/APRIL inhibitor narrative.
View signal analysis